NDA 203752 · Noven
Minivelle
Estradiol · Transdermal · Estrogen
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Oct 29, 2012
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1,701
351 Phase 3, 176 recruiting
FAERS reports
49,932
22,740 serious, 915 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ENDOMETRIAL CANCER WITH UNOPPOSED ESTROGEN IN WOMEN WITH A UTERUS There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen-only therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in menopausal women with abnormal genital bleeding of unknown etiology [see Warnings and Precautions ( 5.2 )] . WARNING: ENDOMETRIAL CANCER WITH UNOPPOSED ESTROGEN IN WOMEN WITH A UTERUS See full prescribing information for complete boxed warning. There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens ( 5.2 )
What it is approved for
From the label in effect Nov 10, 2026.
MINIVELLE is indicated for: MINIVELLE ® is an estrogen indicated for: Treatment of moderate to severe vasomotor symptoms due to menopause ( 1.1 ) Prevention of postmenopausal osteoporosis ( 1.2 ) Limitations of Use When prescribing solely for the treatment of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis. 1.1 Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause 1.2 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis. 1.1 Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause 1.2 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis.
Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 23, 2014 Supplement 4 · Efficacy LabelLetter
- Oct 29, 2012 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
5 products under this application
- MINIVELLE · ESTRADIOL 0.1MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB3
- MINIVELLE · ESTRADIOL 0.075MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB3
- MINIVELLE · ESTRADIOL 0.025MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB3
- MINIVELLE · ESTRADIOL 0.05MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB3
- MINIVELLE · ESTRADIOL 0.0375MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB3
Clinical trials
Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- Short-term Effects of Transdermal Estradiol on Female COVID-19 PatientsPivotal-lookingCompleted
Istanbul University - CerrahpasaAcademic, hospital or other
NCT05774405 · 9,169 participants · Start Jul 1, 2020 · Primary completion Jul 31, 2021
Drug: Climara 0.1Mg/24Hr Transdermal System · For: COVID-19; Hormone Replacement Therapy
Sites: Istanbul, Turkey (Türkiye)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Women's HealthTeva (TEVA)
NCT00996580 · 3,597 participants · Start Oct 2009 · Primary completion Sep 2011
Drug: DR-103 · For: Pregnancy Prevention
Sites: Montgomery, Alabama; Phoenix, Arizona; Tucson, Arizona · 94 sites in all
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)Pivotal-lookingTerminated
Organon and CoIndustry
NCT01656434 · 3,173 participants · Start Nov 2, 2012 · Primary completion Feb 12, 2014
Drug: NOMAC-E2; NETA-EE and 2 more · For: Contraception
- Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral ContraceptivePivotal-lookingTerminated
Organon and CoIndustry
NCT05264506 · 3,055 participants · Start Feb 17, 2022 · Primary completion Jan 12, 2024
Drug: NOMAC-E2 COC · For: Contraception
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 103 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
- A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01178125 · 2,858 participants · Start Aug 2010 · Primary completion Jan 2013
Drug: DR-102 · For: Contraception; Female Contraception
Sites: Montgomery, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 62 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,228
- headache3,036
- nausea2,980
- fatigue2,930
- off label use2,894
- pain2,116
- diarrhoea1,990
- product adhesion issue1,969
- dizziness1,780
- hot flush1,710
- breast cancer female1,709
- arthralgia1,687
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 524 |
| 2005 | 571 |
| 2006 | 402 |
| 2007 | 1,461 |
| 2008 | 428 |
| 2009 | 598 |
| 2010 | 952 |
| 2011 | 840 |
| 2012 | 1,138 |
| 2013 | 1,364 |
| 2014 | 1,835 |
| 2015 | 2,392 |
| 2016 | 2,676 |
| 2017 | 2,464 |
| 2018 | 2,684 |
| 2019 | 3,016 |
| 2020 | 2,958 |
| 2021 | 2,883 |
| 2022 | 3,096 |
| 2023 | 3,581 |
| 2024 | 3,737 |
| 2025 | 5,300 |
| 2026 | 5,031 |
Recalls
10 FDA enforcement reports for this application.
Apr 16, 2021 · Class II · Terminated
Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not...
Apr 16, 2021 · Class II · Terminated
Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not...
Sep 7, 2018 · Class II · Terminated
Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.
Sep 7, 2018 · Class II · Terminated
Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.
Sep 7, 2018 · Class II · Terminated
Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.
Sep 7, 2018 · Class II · Terminated
Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.
May 4, 2018 · Class II · Terminated
Defective Delivery System: no longer meets the specification for shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well...
May 4, 2018 · Class II · Terminated
Defective Delivery System: no longer meets the specification for shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well...
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Minivelle (Estradiol)
2024 spending
$1.3M
Beneficiaries
660
2,918 claims
Per beneficiary
$1,934
$27.62 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,921,982 |
| 2021 | $1,706,370 |
| 2022 | $1,505,764 |
| 2023 | $1,416,918 |
| 2024 | $1,276,110 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Soy Isoflavones on Measures of Estrogenicity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Viscardi G, Back S, Ahmed A, et al. · Adv Nutr 2025 · Systematic Review, Meta-Analysis
- Systematic Review and Meta-analysis: Changes of Gut Microbiota before and after Menopause.
Yang M, Wen S, Zhang J, et al. · Dis Markers 2022 · Meta-Analysis, Systematic Review
- Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.
Hodis HN, Mack WJ, Henderson VW, et al. · N Engl J Med 2016 · Comparative Study, Randomized Controlled Trial
- The Effect of Sex Hormones on Joint Ligament Properties: A Systematic Review and Meta-analysis.
Gilmer G, Crasta N, Tanaka MJ · Am J Sports Med 2025 · Systematic Review, Meta-Analysis
- Association Between Estradiol and Human Aggression: A Systematic Review and Meta-Analysis.
Wang Y, Wang H, Cai J, et al. · Psychosom Med 2023 · Meta-Analysis, Systematic Review
- Pharmacological Treatments for Menopausal Vasomotor Symptoms: A Systematic Review and Bayesian Network Meta-Analysis of Efficacy and Safety.
Oliveira Amador WF, Saraiva CA, Ruelas MG, et al. · Eur J Obstet Gynecol Reprod Biol 2025 · Network Meta-Analysis, Systematic Review
Sponsor: Noven
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.